BDC on X
Pending Boom in brain medicine? Can buy $STIM today and get the clinic piece for free https://t.co/D0U2Qyriyo
NASDAQ
Neuronetics, Inc.
STIM
6 stories
$166M Market cap · 2026-10-09
BDC on X
Very constructive development here w/ $STIM. We have both the largest shareholder and a major activist investor demonstrating full confidence in the balance sheet and new management. We think the new CFO has helped here and credit to Dan Reuvers for taking the CEO role at a tricky time but demonstrating a solid turnaround plan that has obviously has the backing of shareholders. For too long this business has under-punched its weight which is why activism became a reality in the first place. Clearly the new management has things pointed in a more exciting direction. At the same time, shareholder board nominations will ensure that the new direction remains one intent on maximizing equity value.
BDC on X
$STIM https://t.co/VyAQNzsKuH
BDC on X
$STIM https://t.co/OQ9UgUPoo4
BDC on X
Forget AI. Big Pharma is telling us where the next mega theme is. As some have postulated, health care is undergoing extraordinary change. From GLP1s to Peptides to value based Oncology care ($TOI) and of course - the emerging frontier of Psychedelics. $STIM owns the clinical distribution infrastructure for this new space. And the current stock price embeds zero (or negative) equity value for their asset. h/t: @QTRResearch
BDC on X
$STIM owns the largest Spravato clinic footprint in the country. FWIW. Greenbrook TMS— it operates ~95 company-run "Treatment Centers" across the US that administer both NeuroStar TMS and Spravato directly to patients, and it explicitly markets itself as the nation's leading provider of these treatments, with over 60,000 patients treated and 2 million+ treatments delivered. That's the closest thing to a "largest clinical distributor of Spravato" in the public markets
Tickers on this page
Companies the stories above are also about, besides STIM.
